

Giuseppe Curigliano

Last DOI update: 12 September 2023

Financial Interests

Roche, Invited Speaker, Personal
Roche, Advisory Board, Personal
AstraZeneca, Invited Speaker, Personal
AstraZeneca, Advisory Board, Personal
Daiichi Sankyo, Invited Speaker, Personal
Daiichi Sankyo, Advisory Board, Personal
Novartis, Invited Speaker, Personal
Lilly, Advisory Board, Personal
Pfizer, Invited Speaker, Personal
Pfizer, Advisory Board, Personal
Pfizer, Writing Engagement, Personal
Veracyte, Advisory Board, Personal
BMS, Advisory Board, Personal
Merck, Advisory Board, Personal
Exact Sciences, Advisory Board, Personal
Celcuity, Advisory Board, Personal
Menarini, Advisory Board, Personal, Advisory Board
Gilead, Advisory Board, Personal, Advisory Board
Ellipsis, Other, Personal, Advisory Board
Merck, Research Grant, Institutional, Investigator Initiated Trial
BMS, Funding, Institutional, Phase I studies
Novartis, Funding, Institutional, Phase I studies
AstraZeneca, Funding, Institutional, Phase I studies
Daiichi Sankyo, Funding, Institutional, Phase I studies
Roche, Funding, Institutional, Phase I studies
Blueprint Medicine, Funding, Institutional, Phase I studies
Kymab, Funding, Institutional, Phase I studies
Astellas, Funding, Institutional, Phase I studies
Sanofi, Funding, Institutional, Phase I studies
Philogen, Funding, Institutional, Phase I studies
Relay Therapeutics, Coordinating PI, Institutional, Phase I clinical basket trial

Non-Financial Interests

Consiglio Superiore di Sanità, Officer, Italian National Health Council as Advisor for Ministry of Health
Europa Donna, Advisory Role, Member of the Scientific Council. Patient advocacy association
Fondazione Beretta, Advisory Role, Cancer Research Foundation
Lega Italiana Lotta ai Tumori, Member of Board of Directors, No compensation for this role. This a public national company for cancer prevention
EUSOMA, Officer, Member of the Advisory Council
ESMO, Officer, ESMO Clinical Practice Guidelines Chair
ESMO, Member of Board of Directors, Chair of Clinical Practice Guidelines Committee

Peter Dubsy

Last DOI update: 27 April 2023

Financial Interests

Roche, Other, Institutional, Advisory and Travel support
Merck, Advisory Board, Institutional
Astra Zeneca, Other, Institutional, Advisory, Travel support, invited speaker
Cepheid/Danaher, Coordinating PI, Institutional, Grants to ABCSG
Oncomark, Coordinating PI, Institutional, Grant to ABCSG

Non-Financial Interests

IBCSG/ETOP, Officer, Scientific Committee
IBCSG Pre-Cooperera Trial, Principal Investigator, Co PI

Other

Toolbox Lucerne, Other, Founder of a local therapy network